Wide-scale study will examine efficacy of three Alzheimer's drugs
Test subjects will include 160 adults 'doomed to come down with Alzheimer's
Three drugs intended to stave off the effects of Alzheimer's - the heinous disease that robs the elderly of their memory and the thought process - will be tested in a large scale study on three continents. The study will examine 160 people in Great Britain, the United States and Australia who are genetically disposed to get the condition. The study will take place over five years, at which time the subjects are expected to develop Alzheimer's.
Researchers will follow the subjects with scans and memory tests in the first two years of the study, looking for signs that the drugs are working.
Another study starting next year involves an extended family in Colombia that shares the mutation that causes the disease. A third study will involve people in the U.S., aged 70 and older who seem perfectly healthy and who do not have any known Alzheimer's mutations but who have brain scans that show the disease is manifesting itself.
Studies involving people who already have Alzheimer's have failed. Scientists have begun to call for studies in those who do not yet have the disease, saying that the time to intervene is before the brain is irreversibly damaged. The initial study, where people who are destined to get Alzheimer's unless a drug can stop it is a way to test that idea.
"It's an exciting opportunity," Dr. Ronald Petersen, director of the Alzheimer's disease Research Center at the Mayo Clinic says. Petersen is not involved with the study.
Vice President of Medical and Scientific relations at the Alzheimer's Association Maria C. Carrillo says that the results will come quickly. As researchers simultaneously compare the three approaches to stopping the disease over the five years, they should know which drug -- if any -- is going to work. The association contributed $4.2 million to the study, more than twice as much as it has ever spent on a grant, Carrillo says.
Investigators have found ways of spotting and tracking the progression of the disease before any clinical symptoms appear over the past several years, using brain scans and spinal taps and sensitive tests of memory. Many think they are on the brink of a new era in which drugs can be assessed without waiting for effects on profound symptoms.
Deemed DIAN TU, which stands for Dominantly Inherited Alzheimer's Network Trials Unit, the study is designed to get the most information possible in as short a time as possible. Three-quarters of the subjects will get one of three drugs aimed at beta amyloid, a protein that forms the hard plaques on the brain that are the hallmark of Alzheimer's.
The three drugs were chosen from among 15 that drug companies offered. A committee assessed them, looking for drugs with the best evidence of effectiveness and the least likelihood of dangerous side effects.
Researchers will follow the subjects with scans and memory tests in the first two years of the study, looking for signs that the drugs are working. If one or more seems clearly effective, they will switch all the subjects to it and continue the study, looking for clinical benefits.
The drugs to be tested are gantenerumab, made by Roche, which binds to clumps of amyloid and allows it to be removed from the brain, and two drugs by Lilly. One, known as LY2886721, blocks an enzyme, beta-secretase, used to make amyloid. The other, solanezumab, attaches itself to amyloid that is floating free in the brain before it clumps into plaques, facilitating its removal.
© 2012, Distributed by NEWS CONSORTIUM.
- - -
Pope Benedict XVI's Prayer Intentions for January 2013
General Intention: The Faith of Christians. That in this Year of Faith Christians may deepen their knowledge of the mystery of Christ and witness joyfully to the gift of faith in him.
Missionary Intention: Middle Eastern Christians. That the Christian communities of the Middle East, often discriminated against, may receive from the Holy Spirit the strength of fidelity and perseverance.
Keywords: Alzheimer's disease, experimental drugs, study, Great Britain, U.S., Australia, genetic disposition
Rate This Article
Leave a Comment
More Health News
- HIV resurgent among Navajo tribe as deadly cases spike
- UK to give cancer patients genetic analysis just like Angelina Jolie
- Vitamin D found beneficial in treating asthma symptoms
- Study: Depressed women in 40s, 50s suffer more than twice for stroke risk
- Some experts say it's biologically possible to clone a human
- Study: Women live longer than men as their immune systems age more slowly
- Man declared dead for 40 minutes brought back to life with revolutionary machine
- IPad2 poses risks to those with pacemakers, 14-year-old girl discovers
- New SARS-like virus can likely be spread person-to-person
- Fr. Paul Schenck: Finding Living Faith on Catechetical Sunday
- The Movie Yellow: Incest as 'Normal' and Cassavates's Slides Into the World of Woes
- The Chicago School Teachers Strike Reveals the Need For School Choice
- The Sexual Barbarians and the Dissolution of Culture
- The Happy Priest Challenges Us to Ask: Who is Jesus to Me?
- Michael Coren on Canadian Public Schools: Teachers, leave those kids alone
- We Cannot Ignore Our Consciences: Cardinal Dolan On Religious Liberty
- In the Face of Danger, Successor of Peter Travels to Lebanon as a Messenger of Peace
- Reflections on the Dignity and Vocation of Women: Who or What?